← Back to Search

P200TE vs Spectral OCT/SLO Imaging for Retinal Disease

N/A

Waitlist Available

Research Sponsored by Optos, PLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Subjects diagnosed with ocular disease including but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Central Serous Retinopathy, Macular Hole, Epiretinal Membrane, Macular Edema, Glaucoma, and others in the retinal disease study eye(s) as confirmed at the study visit or within the past six (6) months.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up completion of the study, up to 5 years

Awards & highlights

Study Summary

This trial will compare the performance of a new OCT device to the current standard.

Who is the study for?

This trial is for adults over 18 with vision no worse than 20/400 due to various retinal diseases, including macular degeneration and glaucoma. Participants must be able to understand and sign a consent form, follow instructions, and attend scheduled exams. Those who can't tolerate eye imaging or have unclear ocular media, leukemia, dementia, or multiple sclerosis cannot join.Check my eligibility

What is being tested?

The study compares two devices: the new Optos P200TE and the existing Spectral OCT/SLO in scanning eyes affected by retinal disease. It aims to evaluate which device performs better in capturing detailed images of the retina's condition.See study design

What are the potential side effects?

Since this trial involves non-invasive imaging techniques rather than medication or surgery, side effects are minimal but may include discomfort from bright lights during scanning or temporary visual disturbances after the procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with an eye disease like Macular Degeneration or Glaucoma.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ completion of the study, up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~completion of the study, up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and completion of the study, up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cup/Disc Ratio

Optic Nerve Head Topography

Retinal Nerve Fibre Layer Thickness

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: All patientsExperimental Treatment2 Interventions

All patients will be imaged on the P200TE and Spectral OCT/SLO devices.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

P200TE

2019

N/A

~370

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Optos, PLCLead Sponsor

17 Previous Clinical Trials

3,495 Total Patients Enrolled

6 Trials studying Glaucoma

483 Patients Enrolled for Glaucoma

Optos, Inc.UNKNOWN

Media Library

All patients Clinical Trial Eligibility Overview. Trial Name: NCT02921568 — N/A

Glaucoma Research Study Groups: All patients

Glaucoma Clinical Trial 2023: All patients Highlights & Side Effects. Trial Name: NCT02921568 — N/A

All patients 2023 Treatment Timeline for Medical Study. Trial Name: NCT02921568 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings for participants in this clinical experiment?

"As per the clinicaltrials.gov database, this particular medical study is no longer open to recruitment. It was first posted on September 1st 2016 and its most recent update was on March 13th 2017. However, there are 298 other trials presently recruiting patients for participation in their respective studies."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

2016. "Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02921568.

All > Glaucoma Austin > Glaucoma